Telehealth company Hims & Hers reported first-quarter results late Monday that beat Wall Street estimates. But parts of the ...

Hims & Hers stock has risen by 20% after announcing a partnership to sell the popular weight-loss drug Wegovy.

The company reported adjusted earnings per share of $0.28 on revenue of $586 million – a significant rise compared to last ...

Hims & Hers Health, Inc.'s subscriber growth, Novo Nordisk partnership, and FDA pill approval could boost financials. Click ...

Hims & Hers Health, Inc.'s Q1 results show 111% growth, yet shares fell 8%. Click for a look at the impact of drug access, ...

Shares of telehealth company Hims & Hers Health (NYSE:HIMS) jumped 20.2% in the afternoon session after the company reported ...

Stocks fell on Tuesday as Wall Street reacted to the latest round of tariff uncertainty and some mixed earnings reports.These ...

Hims & Hers shares fell in extended trading on Monday after the company reported first-quarter earnings that offered soft ...

But Hims & Hers' shares fell in after-hours trading as second-quarter projections fell short of analysts' expectations. The ...

Hims & Hers launched a pharmacy-made weight-loss drug last year, taking advantage of an FDA rule allowing it to temporarily ...

Hims & Hers Health (NYSE:HIMS) reported a strong financial performance for Q1 2025, with revenue reaching $586 million, ...

Hims & Hers Health Inc. posted better-than-expected first-quarter revenue as the company pivots away from making copycat ...